Targeted Protein Degradation: PROTAC Molecular Architecture, Key Components and Development Landscape

Targeted Protein Degradation: PROTAC Architecture and Development Landscape

1. Overview of PROTAC Molecular Architecture

PROTAC, short for proteolysis-targeting chimera, is a heterobifunctional small molecule. It contains three distinct parts: an E3 ubiquitin ligase ligand, a ligand that binds the intended target protein, and a linker that connects the two ligands, forming a target-ligand–linker–E3-ligand "triad" construct. PROTACs work by reducing the spatial distance between the target protein and the intracellular E3 ubiquitin ligase, directing the target protein to specific degradation through the ubiquitin-proteasome pathway.

On the basis of the recruitment mechanism of the E3 ligase, PROTACs are commonly grouped into five types. Fig. 1 illustrates the molecular structures of the different PROTAC classes, while Fig. 2 summarises the principal target degradation strategies and their mechanisms.

2. Mechanism of Action

Conventional small-molecule inhibitors rely on sustained occupation of the target active site, which brings well-known limitations: acquired resistance, high dosing requirements and a restricted target space. Many transcription factors and scaffold proteins involved in tumour and inflammatory disease have long been classified as undruggable.

PROTACs, as bifunctional small molecules combining a target ligand, a linker and an E3 ligase ligand, exploit the intrinsic ubiquitin-proteasome system (UPS) of the cell to completely eliminate the pathogenic target protein. This confers several distinctive advantages: catalytic mode of action, activity in the nanomolar range, low propensity for resistance and a broad target space. PROTACs currently in clinical development target AR, ER, BTK, IKZF1/3, BRD9, Bcl-xL and IRAK4. Alongside PROTACs, other targeted degradation modalities include other targeted protein degradants, LYTAC and AUTOTAC.

3. Target-Binding Ligands

The target-binding ligand and the E3 ligase ligand are joined through the linker to form the complete PROTAC molecule. The target ligand determines which protein is degraded, and by binding it the PROTAC promotes ubiquitin attachment and subsequent proteasomal elimination. Targets are typically proteins that drive disease progression. Commonly degraded target classes include kinases (for example MEK, KRAS, CDK and Bcr/Abl), transcription factors (p53, STAT, RAR, ER and AR), epigenetic targets (HDAC and BET bromodomains) and E3 ligases themselves (MDM2). Fig. 3 summarises a screening scheme in which E3 recruitment ligands are matched to the specific pathological environment and target class, thereby optimising the functional performance of the degrader.

4. E3 Ubiquitin Ligase Ligands

The catalytic transfer of ubiquitin by E3 ligase determines the specificity of degradation. Although hundreds of E3 ligases exist in the cell, only a small number have been successfully exploited in reported PROTACs, principally VHL (von Hippel-Lindau tumour suppressor protein), CRBN (cereblon), MDM2 and IAP (inhibitor of apoptosis protein). Rational and strategic selection of E3 ligases is the key determinant of the target-specific pharmacological profile of a degrader in a given technical scenario.

5. PROTAC Linkers

A PROTAC is a heterobifunctional degrader with potential as a targeted therapeutic for cancer, and the linker plays a decisive role by connecting the target-binding moiety and the E3 recruitment moiety. Linker characteristics, including type, length and attachment site, influence formation of the E3-linker-target ternary complex and therefore the efficient ubiquitination and degradation of the target. The optimal linker length has been reported to range from 12 to more than 20 carbons, and PEG, alkyl chains and alkyl/ether linkers are those most frequently used in PROTAC development.

6. PROTAC Ligand-Linker Conjugates

6.1 Target-ligand-linker conjugates

Target-ligand-linker conjugates form one half of the PROTAC scaffold. When joined with an E3 ligase ligand they become a complete molecule capable of inducing ubiquitination and subsequent degradation of the target protein.

6.2 E3-ligand-linker conjugates

E3-ligand-linker conjugates constitute the other half of the scaffold. Coupling them to a target ligand (for example JQ1 for BRD4, or Molibresib for BET) yields PROTACs capable of inducing ubiquitination and degradation of the target. Many PROTACs have been reported to show biological activity by selectively targeting BET, the estrogen receptor or the androgen receptor.

7. Scope of Current PROTAC Development

Targeted protein degradation has become an established modality across the research reagent market, spanning target ligands, E3 ubiquitin ligase ligands, various linker chemistries, ligand-linker conjugates and mature PROTAC degraders. The expansion of PROTAC programmes for AR, ER, BTK, IKZF1/3, BRD9, Bcl-xL and IRAK4 into clinical development, together with the development of LYTAC and AUTOTAC alternatives, indicates that the field continues to broaden rapidly.

References

1. Zhao, J., Chen, H. & Liang, C. Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation. Biomark Res 13, 111 (2025). doi:10.1186/s40364-025-00826-7

2. Yin, L., Shu, P. & Peng, X. Context matters: E3 ligase-ligand pairing strategies for optimized targeted protein degradation. Drug Discovery Today (2024).

Contact Absin

Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.

Absin Bioscience Inc. worldwide@absin.cn

Follow us on Facebook: Absin Bio